Jun 2026 (Q2 FY26) — Jul 30, 2026
Myriad Genetics Q2 FY26 — Revenue Decline Amid Payer Friction, Guidance Lowered, Strategic Initiatives Underway
Read the full callMyriad Genetics (MYGN) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Myriad Genetics earnings: last reported Thu, 30 Jul 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 191 | −10.5% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -20.4 | +134.1 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -43.2 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$4.21 +5.78% · +$0.23
Performance −46.0% 1Y
1Y: $7.8 on 17 Oct 2025 → $4.21. High $8.18 (3 Nov 2025), low $2.86 (31 Jul 2026).
- Previous close
- $3.98
- 52-week range
- $2.86 – $8.18
- One year
- −46.71%
Overview
- Symbol
- MYGN
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Myriad Genetics earnings calls (MYGN)
Financials
What the filings say
Net profit, year on year: +87% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 213 | 211 | 196 | 213 | 206 | 210 | 200 | 191 |
| Expenses | 233 | — | — | — | — | — | — | — |
| Operating profit | -20 | -39 | -29 | -329 | -23 | -6 | -31 | -39 |
| Operating margin | −9.4% | −18.6% | −14.8% | −154.5% | −11.3% | −2.7% | −15.3% | −20.4% |
| Other income | -1 | -0 | -0 | -1 | -3 | -3 | -3 | -4 |
| Interest | 1 | 1 | 1 | 2 | 4 | 4 | 4 | 4 |
| Profit before tax | -21 | -39 | -29 | -331 | -26 | -9 | -34 | -43 |
| Tax rate | −4.3% | −8.4% | 99.7% | 0.0% | −4.6% | 11.2% | 0.0% | −1.4% |
| Net profit | -22 | -42 | -0 | -330 | -27 | -8 | -34 | -43 |
| EPS ($ per share) | -0.24 | — | 0 | -3.57 | -0.29 | — | -0.36 | -0.46 |
| Line item | Jun 2019 | Jun 2020 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Reserves | 26 | -174 | -227 | -254 | -366 | -629 | -757 | -1,123 |
| Total liabilities | 474 | 486 | 538 | 353 | 313 | 363 | 327 | 339 |
| Fixed assets | 57 | 37 | 41 | 44 | 83 | 119 | 117 | 114 |
| Investments | 44 | 54 | 34 | 81 | 58 | 9 | 0 | — |
| Total assets | 1,563 | 1,405 | 1,419 | 1,321 | 1,199 | 1,147 | 1,028 | 707 |
| Line item | Jun 2018 | Jun 2019 | Jun 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 116 | 84 | 61 | 19 | -106 | -111 | -9 | 2 |
| Cash from investing | -12 | -286 | 19 | 274 | -77 | 32 | -12 | -27 |
| Cash from financing | -95 | 182 | -10 | -151 | -8 | 153 | -7 | 64 |
| Net cash flow | 9 | -18 | 71 | 142 | -192 | 75 | -29 | 39 |
| Capital expenditure | -8 | -9 | -10 | -18 | -45 | — | — | — |
| Free cash flow | 108 | 75 | 51 | 1 | -152 | — | — | — |
Insider filings
63 filings between Dec 11, 2025 and Sep 21, 2026.
Open market
decisions to buy or sellPurchases
$722.2K
5 purchases by 3 insiders
Sales
$66.8K
1 sale by 1 insider
100% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 23
- Award — granted as compensation
- 34
- Tax withheld — shares kept back by the company to cover tax
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Phanstiel S. Louise | $494.7K | — | Feb 27, 2026 |
| Raha Samraat S. | $199.8K | — | Mar 9, 2026 |
| Kumar Rashmi | — | $66.8K | Jun 8, 2026 |
| BISARO PAUL | $27.6K | — | May 14, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 21, 2026 | Wheeler Benjamin Richard Chief Financial Officer | Tax withheld | 2,555 | $10.2K |
| Sep 16, 2026 | Sikri Vishal EVP, Commercial | Award | 257,731 | $0 |
| Sep 3, 2026 | Fox Jennifer Lynne Chief Legal Officer | Tax withheld | 4,398 | $14.2K |
| Aug 16, 2026 | Wheeler Benjamin Richard Chief Financial Officer | Tax withheld | 8,761 | $26.5K |
| Jun 11, 2026 | Raha Samraat S. President and CEO | Award | 3,542 | $13.9K |
| Jun 11, 2026 | Donnelly Brian J Chief Commerical Officer | Award | 5,000 | $19.7K |
| Jun 8, 2026 | Kumar Rashmi Director | Sale 10b5-1 plan | 15,000 | $66.8K |
| Jun 4, 2026 | Davis Mark Steven Director | Award | 59,701 | $0 |
| Jun 4, 2026 | Skovronsky Daniel Director | Award | 59,701 | $0 |
| Jun 4, 2026 | Dreismann Heinrich Director | Award | 59,701 | $0 |
| Jun 4, 2026 | Reitan Colleen F Director | Award | 59,701 | $0 |
| Jun 4, 2026 | Newcomer Lee Nisley Director | Award | 59,701 | $0 |
| Jun 4, 2026 | Kumar Rashmi Director | Award | 59,701 | $0 |
| Jun 4, 2026 | BISARO PAUL Director | Award | 59,701 | $0 |
| Jun 4, 2026 | Phanstiel S. Louise Director | Award | 59,701 | $0 |
| Jun 1, 2026 | Jampa Raj Chief Technology Officer | Award | 251,889 | $0 |
| May 14, 2026 | BISARO PAUL Director | Purchase | 7,500 | $27.6K |
| May 1, 2026 | Donnelly Brian J Chief Commerical Officer | Tax withheld | 55,975 | $268.7K |
| Apr 14, 2026 | Muzzey Dale Chief Scientific Officer | Tax withheld | 946 | $4.6K |
| Apr 14, 2026 | Verratti Mark Chief Operating Officer | Tax withheld | 1,069 | $5.2K |
| Mar 22, 2026 | Muzzey Dale Chief Scientific Officer | Tax withheld | 2,019 | $9.2K |
| Mar 22, 2026 | Verratti Mark Chief Operating Officer | Tax withheld | 2,055 | $9.4K |
| Mar 22, 2026 | Wheeler Benjamin Richard Chief Financial Officer | Tax withheld | 549 | $2.5K |
| Mar 15, 2026 | Verratti Mark Chief Operating Officer | Tax withheld | 9,096 | $42.4K |
| Mar 15, 2026 | Verratti Mark Chief Operating Officer | Tax withheld | 5,611 | $26.1K |
| Mar 15, 2026 | Wheeler Benjamin Richard Chief Financial Officer | Tax withheld | 2,192 | $10.2K |
| Mar 15, 2026 | Wheeler Benjamin Richard Chief Financial Officer | Tax withheld | 877 | $4.1K |
| Mar 15, 2026 | Muzzey Dale Chief Scientific Officer | Tax withheld | 4,783 | $22.3K |
| Mar 15, 2026 | Haas Kevin Richard Chief Technology Officer | Tax withheld | 8,382 | $39.1K |
| Mar 15, 2026 | Haas Kevin Richard Chief Technology Officer | Tax withheld | 3,355 | $15.6K |
| Mar 15, 2026 | Muzzey Dale Chief Scientific Officer | Tax withheld | 11,949 | $55.7K |
| Mar 14, 2026 | Raha Samraat S. President and CEO | Tax withheld | 10,816 | $50.4K |
| Mar 14, 2026 | Verratti Mark Chief Operating Officer | Tax withheld | 5,418 | $25.2K |
| Mar 14, 2026 | Wheeler Benjamin Richard Chief Financial Officer | Tax withheld | 1,097 | $5.1K |
| Mar 14, 2026 | Muzzey Dale Chief Scientific Officer | Tax withheld | 8,288 | $38.6K |
| Mar 14, 2026 | Solaiman Shereen Chief People Officer | Tax withheld | 5,784 | $27.0K |
| Mar 14, 2026 | Haas Kevin Richard Chief Technology Officer | Tax withheld | 4,161 | $19.4K |
| Mar 13, 2026 | Raha Samraat S. President and CEO | Tax withheld | 36,304 | $169.2K |
| Mar 13, 2026 | Verratti Mark Chief Operating Officer | Tax withheld | 9,164 | $42.7K |
| Mar 13, 2026 | Wheeler Benjamin Richard Chief Financial Officer | Tax withheld | 586 | $2.7K |
| Mar 13, 2026 | Muzzey Dale Chief Scientific Officer | Tax withheld | 12,779 | $59.6K |
| Mar 13, 2026 | Haas Kevin Richard Chief Technology Officer | Tax withheld | 6,412 | $29.9K |
| Mar 13, 2026 | Fox Jennifer Lynne Chief Legal Officer | Tax withheld | 5,995 | $27.9K |
| Mar 13, 2026 | Solaiman Shereen Chief People Officer | Tax withheld | 8,899 | $41.5K |
| Mar 12, 2026 | Raha Samraat S. President and CEO | Award | 618,557 | $0 |
| Mar 12, 2026 | Verratti Mark Chief Operating Officer | Award | 247,423 | $0 |
| Mar 12, 2026 | Solaiman Shereen Chief People Officer | Award | 173,196 | $0 |
| Mar 12, 2026 | Wheeler Benjamin Richard Chief Financial Officer | Award | 206,186 | $0 |
| Mar 12, 2026 | Donnelly Brian J Chief Commerical Officer | Award | 226,804 | $0 |
| Mar 12, 2026 | Muzzey Dale Chief Scientific Officer | Award | 173,196 | $0 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for MYRIAD GENETICS INC
Free account. Everything above stays public.
Write why you follow MYRIAD GENETICS INC and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading